GSK is found guilty of offering bribes to doctors and is fined $489 million.
A court in China has found GlaxoSmithKline’s China Investment Co. Ltd. guilty of bribing doctors to use the company’s drugs and has imposed a fine of $489 million (3 billion yuan). China’s Ministry of Public Security initiated an investigation in June 2013.
The fine will be funded through existing cash resources, GSK reports in a statement. Associated costs and charges related to restructuring will be included in the company’s third quarter update.
In a statement, GSK announced the fine and reported; "The illegal activities of GSKCI are a clear breach of GSK’s governance and compliance procedures; and are wholly contrary to the values and standards expected from GSK employees. GSK has published a statement of apology to the Chinese government and its people on its website (www.gsk-china.com)."
GSK also reported that the company has cooperated with the authorities and has taken steps to rectify the issues identified at the operations of GSKCI including changing the incentive program for its salesforce; reducing and changing engagement activities with healthcare professionals; and expanding processes for review and monitoring of invoicing and payments.
"Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK. We have and will continue to learn from this. GSK has been in China for close to a hundred years and we remain fully committed to the country and its people. We will continue to expand access to innovative medicines and vaccines to improve their health and well-being. We will also continue to invest directly in the country to support the government's health care reform agenda and long-term plans for economic growth," said GSK Chief Executive Officer, Sir Andrew Witty in a statement.
Source: GlaxoSmithKline
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.